QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=E65F5FF2579828E3957F6EC0659BC027;jsessionid=C22459D1FC782BBF88AE726AB2ED8519;jsessionid=63DE3311F32126CEC93952F329EA64C4;jsessionid=F6412630D706C33E7B63DA029F3A31E8;jsessionid=725E74B34D7DD09263CCB33F79E805B1;jsessionid=E698E5910F80E70B1A82F4EA9A5245E6;jsessionid=A610FE886BDC05C1E990BB9F9C384C95;jsessionid=C4C3B8FA82FE7DF72A7019ABB6926C3C (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=E65F5FF2579828E3957F6EC0659BC027;jsessionid=C22459D1FC782BBF88AE726AB2ED8519;jsessionid=63DE3311F32126CEC93952F329EA64C4;jsessionid=F6412630D706C33E7B63DA029F3A31E8;jsessionid=725E74B34D7DD09263CCB33F79E805B1;jsessionid=E698E5910F80E70B1A82F4EA9A5245E6;jsessionid=A610FE886BDC05C1E990BB9F9C384C95;jsessionid=C4C3B8FA82FE7DF72A7019ABB6926C3C